Greenwich LifeSciences, Inc. GLSI

GLSI Company Overview

Greenwich LifeSciences, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on the development of immunotherapy products for cancer treatment. The company operates within the biotechnology and oncology sectors, with its primary emphasis on breast cancer immunotherapy. Greenwich LifeSciences’ lead product candidate is GP2, a peptide-based immunotherapy designed to prevent breast cancer recurrence in patients who express HER2/neu, particularly those who have previously undergone surgery and standard treatment regimens. The company generates no significant commercial product revenue as of publicly available filings and primarily finances operations through equity offerings and capital market activity typical of development-stage biotechnology firms.

The company traces its origins to research conducted at the University of Texas MD Anderson Cancer Center and later advanced through licensing and clinical development efforts. Greenwich LifeSciences became publicly traded in the United States and has positioned itself as a specialized oncology immunotherapy developer focused on reducing recurrence rates in high-risk breast cancer patients. Its strategic differentiation centers on targeting recurrence prevention rather than treatment of advanced metastatic disease, an area with comparatively fewer approved immunotherapeutic options.